References
- Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. Gen Pharmacol 1996;27:745–8.
- Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anti-cancer Drug 1998;9:319–25.
- Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Sersa G. Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Brit J Cancer 2001;84:565–70.
- Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim Biophys Acta 2002;1569:51–8.
- Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013;39:4–16.
- Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek JJr, Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993;72:3694–700.
- Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998;83:148–57.
- Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 2009;16:191–9.
- Mir LM, Gehl J, Sersa G, Collins CG, Garbay J-R, Billard V, et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin and cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator by means of inasive or noninvasive electrodes. Eur J Cancer Suppl 2006;4(11):14–25.
- Burian M, Formanek M, Regele H. Electroporation therapy in head and neck cancer. Acta Otolaryngol 2003;123:264–8.
- Panje WR, Hier MP, Garman GR, Harrell E, Goldman A, Bloch I. Electroporation therapy of head and neck cancer. Ann Oto Rhinol Laryn 1998;107:779–85.
- Landstrom FJ, Nilsson CO, Reizenstein JA, Nordqvist K, Adamsson GB, Lofgren AL. Electroporation therapy for T1 and T2 oral tongue cancer. Acta Otolaryngol 2011;131:660–4.
- Landstrom FJ, Reizenstein JA, Nilsson CO, Beckerath MV, Lofgren AL, Adamsson GB, et al. Electrochemotherapy - possible benefits and limitations to its use in the head and neck region. Acta Otolaryngol 2015;135:90–5.
- Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999;17:1008–19.
- Fayers PM, Aaronson NK, Bjordal K, Groenwold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
- Allegretti JP, Panje WP. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001;111:52–6.
- Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryng Head Neck 2004;131:472–6.
- Fukano H, Matsuura H, Hasegawa Y, Nakamura S. Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Head Neck 1997;19:205–10.
- Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer 2008;112:345–51.
- Mitchell R, Crighton LE. The management of patients with carcinoma of the tongue. Br J Oral Max Surg 1993;31:304–8.